Document:

EX-10.1

 Exhibit 10.1 

March 27, 2017 
 CVI Investments, Inc. c/o Heights Capital
Management 
 101 California Street 
 Suite 3250 

San Francisco, CA 94111 

	Attention:	Martin Kobinger, 

	 	Investment Manager 

  

	Re:	Waiver and Consent with respect to the Securities Purchase Agreement and Warrants 

 Dear Sirs: 

Reference is hereby made to that certain Securities Purchase Agreement, dated August 30, 2016, by and among Ampio Pharmaceuticals, Inc., a
Delaware corporation with headquarters located at 373 Inverness Parkway, Suite 200, Englewood, Colorado 80112 (the “Company”), the investor signatory hereto (“you” or the “Investor”) and certain
other buyers signatory thereto (the “Securities Purchase Agreement”), pursuant to which you acquired, among other things, certain warrants to purchase shares of Common Stock (as defined in the Securities Purchase Agreement) (the
“Warrants”) in accordance with the terms of Warrants. Capitalized terms not defined herein shall have the meaning as set forth in the Securities Purchase Agreement or the Warrants, as applicable. 

Pursuant to Section 2(g) of the Warrants, we hereby provide you with notice that the Company desires your consent pursuant to
Section 2(g) of the Warrants (the “Consent”), to lower the Exercise Price of your Warrants for each date after the Effective Time (as defined below) (each, a “Exercise Price Reduction”), effective (the
“Effective Time”) as of the time of your execution of this letter, to $0.40 (as adjusted for stock splits, stock dividends, stock combinations, recapitalizations and similar events, the “New Exercise Price”). 

The Company further requests that you waive all of your rights pursuant to Section 2(b) of the Warrants with respect to any future
Dilutive Issuance by the Company or any of its Subsidiaries, and Section 2(d) relating to the issuance by the Company of Variable Price Securities (the “Warrant Waivers”). In addition, the Company requests that you waive
Section 4(p) of the Securities Purchase Agreement relating to the prohibition of Variable Rate 

 
Transactions (the “SPA Waiver” and together with the Warrant Waivers, collectively the “Waivers”). The Waivers are permanent and shall be deemed amendments to
the Warrants and Securities Purchase Agreement. 
 As additional consideration for the Consent, Exercise Price Reduction and Waiver, the
Company hereby agrees that for the period commencing on the date hereof and ending on the date immediately following the 10th Trading Day after the date of your execution of this letter (the
“Restricted Period”), neither the Company nor any of its Subsidiaries shall, directly or indirectly, issue, or sell (or announce any issuance or sale), directly or indirectly, any equity security or any equity-linked or related
security (including, without limitation, any “equity security” (as that term is defined under Rule 405 promulgated under the 1933 Act)), any Convertible Securities (as defined below), any debt, any preferred stock or any purchase rights
(in each case, other than Excluded Securities (as defined in the Securities Purchase Agreement). 
 Please execute this letter in the
signature block below if you agree to the Consent, Exercise Price Reduction and the Waiver. 
 The Company shall, on or before 8:30 a.m.,
New York City time, on the first business day after the date of this letter, issue a press release and Current Report on Form 8-K disclosing all material terms of the transactions contemplated hereby and attaching the form of this letter as an
exhibit thereto (collectively with all exhibits attached thereto, the “Press Release”). From and after the issuance of the Press Release, the Investor shall not be in possession of any material, nonpublic information received from
the Company or any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents, that is not disclosed in the Press Release. In addition, effective upon the issuance of the Press Release, the Company
acknowledges and agrees that any and all confidentiality or similar obligations under any letter, whether written or oral, between the Company, any of its subsidiaries or any of their respective officers, directors, affiliates, employees or agents,
on the one hand, and the Investor or any of its affiliates, on the other hand, shall terminate and be of no further force or effect. The Company understands and confirms that the Investor will rely on the foregoing representations in effecting
transactions in securities of the Company. 
 Section 9 of the Securities Purchase Agreement is hereby incorporated by reference
herein, mutatis mutandis. 

 If you have any questions regarding the foregoing, please feel free to contact the Company’s
chief financial officer at (720) 437-6500 or by email to ggould@ampiopharma.com. 
  

			
	 Sincerely,
  

AMPIO PHARMACEUTICALS, INC.

		
	By:	 	/s/ Michael Macaluso
		 	 Name: Michael Macaluso
 Title:
CEO

 As evidenced by the below signature, the Investor hereby agrees to the Consent, Exercise Price Reduction and the Waiver
as of this 27th day of March, 2017: 
  

			
	CVI INVESTMENTS, INC.
		
	By:	 	/s/ Martin Kobinger
		 	 Name: Martin Kobinger
 Title: Investment
ManagerExhibit

Exhibit 10.2g
        
RESTRICTED STOCK AWARD AGREEMENT - Employee
CALERES, INC.
INCENTIVE AND STOCK COMPENSATION PLAN OF 2011

Caleres, Inc., a New York corporation (the “Company”), grants to the participant identified below an award of Restricted Shares, which shall be shares of the Company’s Common Stock, $.01 par value (“Common Stock”), pursuant to the provisions of the Incentive and Stock Compensation Plan of 2011 (the “Plan”), and subject to the key terms set forth below and the attached General Terms and Conditions (dated as of March 3, 2016), including restrictions applicable to the Restricted Shares, all of which constitute part of this Agreement (the “Restricted Stock Award”), as follows:

Participant:     

Award Grant Date:                       

Number of Restricted Shares:        Shares of Caleres, Inc. Common Stock,
subject to certain restrictions.

Vesting Schedule (Lapse of Restrictions):  Twenty-five percent (25%) annually starting one year from the Grant Date
                        

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed effective as of the date written below.

CALERES, INC.

By:
_______________________

Becky Helvey
Sr. Manager, Compensation
Date: 

Accepted: __________________________________
Participant

Date: _____________________________________

RESTRICTED STOCK AWARD
General Terms and Conditions (as of March 3, 2016)  

Incentive and Stock Compensation Plan of 2011 

1.  Restrictions

The Restricted Shares are restricted as to disposition and may not be pledged; and are subject to forfeiture unless certain conditions are met.  The Company’s transfer agent has been advised that the Restricted Shares cannot be sold, transferred, re-registered or disposed of until the restrictions on the shares lapse.  Restricted Shares shall vest, and the restrictions shall no longer apply, as to the number or percentage of Restricted Shares and on the dates specified above as the “Vesting Schedule.” A further restriction on the Restricted Shares is that you shall only be entitled to receive Shares free of restrictions if, at the time of the lapse of such restrictions, you are then in the employ of the Company and shall have been continuously so employed since the date of grant of the Restricted Shares.  If you do not meet these conditions at any time, such Shares shall be forfeited.  

2.  Voting Rights and Dividend Rights

You will be entitled to full voting rights and dividend rights for all Restricted Shares, beginning with the date of grant, regardless of restriction periods.  Dividends may be paid directly to you or may be credited to your dividend re-investment plan account.  Dividend rights and voting rights will be cancelled in the event the Restricted Shares are forfeited.

3.  Book Entry for Restricted Shares.  You will not receive a certificate for the Restricted Shares; instead, the Restricted Shares will be credited as a book entry to an account in your name with the Company’s transfer agent.  At such time as the restrictions lapse, those Shares that are no longer subject to restrictions shall be transferred to a non-restricted account in your name with the transfer agent or as otherwise directed by you and agreed by the Company.

4.  Death, Disability or Retirement.  In the event of termination of employment due to death, permanent Disability, or retirement (including but not limited to any early retirement) if approved by the Compensation Committee, all Restricted Shares shall vest immediately and be free of restrictions.  
    
5.  Change in Control.  Subject to Article 13 of the Plan, unless otherwise specifically prohibited under applicable laws, or by the rules and regulations of any governing governmental agencies or national securities exchange, the Restricted Shares still subject to restrictions under this Agreement shall automatically vest and all restrictions shall lapse as of the vest and all restrictions shall lapse upon the occurrence of a Change in Control.

6.  Adjustment Upon Changes in Capitalization.  In accordance with Section 4.2 of the Plan, in the event that there is a change in the Common Stock of the Company by reason of stock dividends, split-ups, recapitalizations, mergers, consolidations, reorganizations, combinations or exchanges of shares, then the Restricted Shares shall be adjusted in the same manner as other shares of  Common Stock are adjusted.

7.  Tax Withholding.  The Board shall have the power and the right to deduct or withhold, cash or shares, or require the Participant to remit to the Company, an amount sufficient to satisfy Federal, state, and local taxes, domestic or foreign, required by law or regulation to be withheld with respect to any taxable event arising as a result of the Award.

8.  Share Withholding.  With respect to withholding upon the lapse of restrictions on the Restricted Shares, or upon any other taxable event arising as a result of this grant of Restricted Shares, the Participant may elect, subject to the approval of the Board, to satisfy the tax withholding requirement, in whole or in part, by having the Company withhold Shares having a Fair Market Value on the date the tax is to be determined equal to the minimum statutory total tax which could be imposed on the transaction.  All such elections shall be irrevocable, made in writing, signed by the Participant, and shall be subject to any restrictions or limitations that the Board, in its sole discretion, deems appropriate.  Notwithstanding the foregoing, in the event that the Participant has the opportunity to make an election but does not submit to the Company a properly completed election form at least five (5) business days prior to the date of Lapse of Restrictions; or the Participant does not tender cash consideration as elected or required, then Section 7 of these Terms and Conditions may be applied.  

9.  Nontransferability.  This Agreement and the Restricted Shares granted hereunder, until such time as the restrictions on the Shares have lapsed, may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated, other than by will or by the laws of descent and distribution.  

10.  Administration and Interpretation.  This Award Agreement and the rights of the Participant hereunder are subject to all terms and conditions of the Plan, as the same may be amended from time to time, as well as to such rules and regulations as the Board may adopt for administration of the Plan.  It is expressly understood that the Board is authorized to administer, construe, and make all determinations necessary or appropriate to the administration of the Plan and this Award Agreement, all of which shall be binding upon the Participant.  The Board may delegate to the Compensation Committee all determinations with respect to the Plan and this Award Agreement.  All capitalized terms used in this Award Agreement shall have the meanings ascribed to them in the Plan, unless specifically set forth otherwise herein.  If there is any inconsistency between the terms of this Award Agreement and the terms of the Plan, the Plan’s terms shall completely supersede and replace the conflicting terms of this Award Agreement.  

11.  Miscellaneous

		
	(a)
	This Award Agreement shall not confer upon the Participant any right to continuation of employment by the Company, nor shall this Award Agreement interfere in any way with the Company’s right to terminate his or her employment at any time.

    
		
	(b)
	The Board may terminate, amend, or modify the Plan; provided, however, that no such termination, amendment, or modification of the Plan may in any way adversely affect the Participant’s rights under this Award Agreement without the Participant’s written consent.

		
	(c)
	This Award Agreement shall be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.

		
	(d)
	To the extent not preempted by Federal law, this Award Agreement shall be construed in accordance with and governed by the substantive laws of the State of Missouri without regard to conflicts of laws principles, which might otherwise apply.  Any litigation arising out of, in connection with, or concerning any aspect of the Plan or this Award Agreement shall be conducted exclusively in the State or Federal courts in Missouri.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}]]